Not applicableStudy completedNCT02519413What this trial is testingTecfidera Lymphocyte Chart ReviewWho this might be right forMultiple Sclerosis Biogen 483
Testing effectiveness (Phase 2)Study completedNCT03381170What this trial is testingAn Extension of the TG1101-RMS201 TrialWho this might be right forRelapsing Remitting Multiple Sclerosis TG Therapeutics, Inc. 48
Not applicableStudy completedNCT02021162What this trial is testingEffects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple SclerosisWho this might be right forMultiple SclerosisHealthy University at Buffalo 50
Not applicableStudy completedNCT01281657What this trial is testingLong Term Study of Fingolimod in MS Patients From the FTY Clinical ProgramWho this might be right forMultiple Sclerosis Novartis 64
Post-approval studies (Phase 4)Study completedNCT03784898What this trial is testingCollection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving LemtradaWho this might be right forMultiple Sclerosis Genzyme, a Sanofi Company 13
Not applicableStudy completedNCT06251986What this trial is testingA Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical PracticeWho this might be right forRelapsing Forms of Multiple Sclerosis Novartis Pharmaceuticals 310
Not applicableLooking for participantsNCT05658497What this trial is testingPregnancy Exposure Registry for Vumerity (Diroximel Fumarate)Who this might be right forMultiple Sclerosis Biogen 908
Early research (Phase 1)Ended earlyNCT01144351What this trial is testingA Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis Elan Pharmaceuticals 32
Post-approval studies (Phase 4)Study completedNCT03856619What this trial is testingTo Evaluate the Safety and Efficacy of Teriflunomide in Patients With Relapsing Forms of Multiple SclerosisWho this might be right forRelapsing Multiple Sclerosis Sanofi 121
Early research (Phase 1)Study completedNCT01585766What this trial is testingSafety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis, Relapsing Forms MedImmune LLC 56
Early research (Phase 1)Ended earlyNCT02606630What this trial is testing[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis AbbVie 4
Not applicableUnknownNCT01811290What this trial is testingA Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis Simnad, Virginia, M.D. 36
Large-scale testing (Phase 3)Study completedNCT05083923What this trial is testingDiroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)Who this might be right forRelapsing Forms of Multiple Sclerosis Biogen 136
Large-scale testing (Phase 3)Study completedNCT01863888What this trial is testingEffect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple SclerosisWho this might be right forMultiple Sclerosis Sanofi 70
Testing effectiveness (Phase 2)Study completedNCT00640328What this trial is testingOfatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) PatientsWho this might be right forMultiple Sclerosis GlaxoSmithKline 38
Post-approval studies (Phase 4)Study completedNCT00536120What this trial is testingThe Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis Biogen 60
Not applicableStudy completedNCT01158183What this trial is testingReal-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple SclerosisWho this might be right forMultiple Sclerosis, Relapsing-Remitting Bayer 226
Large-scale testing (Phase 3)Not Yet RecruitingNCT07220252What this trial is testingStudy to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisWho this might be right forRelapsing Multiple Sclerosis TG Therapeutics, Inc. 240
Early research (Phase 1)Ended earlyNCT01424423What this trial is testingNOGO-A in Multiple Sclerosis FTIHWho this might be right forMultiple Sclerosis GlaxoSmithKline 3
Large-scale testing (Phase 3)Study completedNCT03277261What this trial is testingStudy to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )Who this might be right forRelapsing Multiple Sclerosis (RMS) TG Therapeutics, Inc. 549